In 2013, Wei’s team predicted that overexpression of FGF18 was an independent marker for poor prognosis of ovarian cancer, and determined that FGF18 was a serum biomarker of ovarian cancer, which was significantly correlated with the prognosis and progression of ovarian cancer (33). Here, FGF18 is linked to ovarian cancer.